AnaptysBio Announces Strategic Split into Two Public Companies

AnaptysBio has confirmed its participation in several upcoming investor conferences, where management will detail a major corporate restructuring. The centerpiece of this strategy is a planned separation of the business into two independent, publicly-traded entities, targeted for completion by the end of 2026.

The company enters this transformative period from a position of financial strength. It anticipates closing its last fiscal year with approximately $300 million in cash and investments. This figure includes a significant one-time $75 million milestone payment from GSK, triggered after the partnered drug Jemperli achieved global net sales of $1 billion. Further financial details and an updated timeline for the separation will be provided when AnaptysBio releases its full fourth-quarter and Read more...